

Ref no: 216200818
From: Public
Date: 20.08.2018
Subject: Plaque Psoriasis

REQUEST

Questions

1. How many patients with plaque psoriasis in your Trust are currently being treated with unlicensed Fumaderm?

2. How many patients with plaque psoriasis in your trust are currently being treated with Skilarence?

3. Is the Trust starting patients with plaque psoriasis on Skilarence?
 - a. If yes to Q3, how many patients in the last 6 months?

4. Is the Trust starting patients with psoriasis on unlicensed Fumaderm?
 - a. If yes to Q4, how many patients in the last 6 months?

5. Does the Trust intend to review all patients with plaque psoriasis taking unlicensed Fumaderm in order to move them to a licensed formulation where appropriate?

6. Please describe the process in place to achieve Q5 and the anticipated completion date.

7. If the Trust does not intend to initiate Skilarence or review all patients with plaque psoriasis taking unlicensed Fumaderm, please provide an explanation why the Trust intends to continue with its current practice.

RESPONSE

We do not use this product.